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Dear Editor, The Coronavirus Disease-2019 (COVID-19) pandemic has slowed down the
solid organ transplantation worldwide. Although, we have heard of few solid organ
transplants having been performed in patients recovered from COVID-19 infection, none
has been reported yet. We present a patient who underwent a simultaneous pancreas and
kidney transplantation (SPK) after recovering from COVID-19 and is doing well close to 2
months post-transplantation. A 66-year-old Caucasian female with end-stage renal disease
(ESRD) secondary to insulin dependent type 2 diabetes mellitus was called in to undergo
SPK. On admission, we found that three months prior, she had been diagnosed with COVID-

of

19 with fever and cough but had recovered completely while in self-quarantine at home. On

ro

her admission, she had stable vitals and physical exam was unremarkable. A COVID-19

-p

antibody test was positive for IgG and COVID-19 rapid PCR test was negative on two
occasions a day apart (Table 1). Other laboratory parameters were unremarkable. The

re

chest x-ray (CXR) and computed tomography (CT) scan of lungs showed no lung

lP

abnormalities. Patient underwent SPK successfully from a COVID-19 negative donor and
had an uneventful post-transplant course. Her serum creatinine trended down to 0.8

na

mg/dL, and she came off insulin by day 4 post-transplant. She received three reduced doses
of Thymoglobulin® (rATG; Sanofi-Genzyme, Cambridge, MA) 1 mg/kg/day for induction

ur

along with intravenous methylprednisolone taper. She was discharged on post-operative

Jo

day 5 on mycophenolate mofetil 500 mg twice a day, extended release tacrolimus
(Envarsus XR) 6 mg once a day (Target Tacrolimus level 7-9 ng/ml), and oral prednisone
taper. Patient has remained asymptomatic with no signs of repeat COVID-19 infection 7
weeks after her transplant.
There were several considerations prior to proceeding with her transplantation. First, had
she successfully cleared the SARS-CoV-2 infection? The detection of COVID-19 by RT-PCR
may yield false negative tests.1,2 This uncertainty in test results is further complicated by
reports of confirmed RT-PCR positive COVID-19 cases who recovered from the illness,
tested negative on repeat RT-PCR but again tested positive afterwards, bringing into
question if this was a repeat infection or if the preceding test results were in fact, falsely
negative.3,4. Our patient had no symptoms or signs of infection, COVID 19 PCR was negative
2

on two occasions a day apart, and a COVID-19 antibody test was positive. Second, could she
have developed a chronic COVID-19 carrier state, and if infection would relapse posttransplant? Many (non-retrovirus) RNA viruses like hepatitis C can establish “within host”
persistent infections that occasionally lead to chronic or reactivated disease.5 Chronic
COVID-19 carrier state has not been reported yet. Our patient exhibited no symptoms or
signs of chronic organ dysfunction and since her transplant, multiple SARS CoV-2 PCR have
stayed negative. Third, will positive SARS-CoV-2 antibodies protect her from repeat
infection? There have been reports of prolonged co-existence of anti-SARS-CoV-2 IgG along

of

with the positive RT-PCR for SARS-CoV-2 raising the possibility of variable level of

ro

immunity provided by the antibodies.6 In a smaller study done by Zhang et al, both IgM and

-p

IgG antibodies were detected in all 39 patients infected with SARS-CoV-2 after 5 days of
disease onset.7 In a report of 149 COVID-19 convalescent individuals who recovered from

re

COVID-19, authors found that most convalescent plasmas collected an average of 39 days

lP

after the onset of symptoms do not contain high levels of neutralizing activity.8 Transplant
patients who are on long term immunosuppression may have attenuated immunity putting

na

them at risk of atypical presentations, delayed or missed diagnoses, and higher morbidity
and possible higher mortality with COVID-19 compared to the general population.9,10 We

ur

lowered the dose of induction and maintenance immunosuppression in our patient to

Jo

retain the positive anti-SARS-CoV-2 antibodies. Although, her total antibodies (IgG and
IgM) have persisted till the time of last follow-up, IgG antibodies became negative at 1week follow-up post-transplant.
In conclusion, this case study suggests that it may be reasonable to proceed with solid
organ transplant in wait-list candidates if they have recovered completely from COVID-19
with no evidence of active infection, after confirming two consecutively negative PCR tests,
and with positive SARS-CoV-2 antibody levels. The role of SARS- CoV-2 antibodies in
providing protection is unclear and levels may fall off rapidly post-transplant probably due
to immunosuppression. Patients must be advised to continue to take safety precautions
post-transplant.
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Table 1. COVID-19 PCR and antibody test results

SARS CoV-2

4/19/2020

7/2/2020

7/3/2020

7/9/2020

7/13/2020

7/16/2020

7/23/2020

7/30/2020

Positive

Negative

Negative

Negative

Negative

Negative

Negative

22.7

31.4

26.3

Reactive

Reactive

RNA by RT
PCR
CoV-2,

19.3

Total Index
(Reference
Range < 1.0

CoV-2,

of

S/C†)
Reactive

Reactive

ro

Total Ab
(IgG and/or

SARS CoV

-p

IgM)
Reactive

1.09

IgG Index

S/C†)

Non-

Non-

Non-

reactive

reactive

reactive

reactive

0.35

0.31

0.36

0.42

0.31

na

(< 1.0

Non-

reactive
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SARS CoV

Non-

re

IgG Ab
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Pack11
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†S/C: Signal for test sample/Signal at cutoff value, VITROS Immunodiagnostic Products Anti-SARS-CoV-2 Total Reagent
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